Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure

Stegmann, Sophie; Manea, Maria Elena; Charpentier, Charlotte; Damond, Florence; Karmochkine, Marina; Laureillard, Didier; Si-Mohamed, Ali; Weiss, Laurence; Piketty, Christophe

doi:10.1016/j.jcv.2009.11.008

« Previous Next »Journal of Clinical Virology
Volume 47, Issue 1 , Pages 79-81, January 2010

Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure

Sophie Stegmann
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
- Université Paris Descartes, Paris, France
Maria Elena Manea
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
Charlotte Charpentier
- Université Paris Descartes, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Paris, France
Florence Damond
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bichat, Laboratoire de Virologie, Paris, France
Marina Karmochkine
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
Didier Laureillard
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
Ali Si-Mohamed
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Paris, France
Laurence Weiss
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
- Université Paris Descartes, Paris, France
Christophe Piketty
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Service d’Immunologie Clinique, Paris, France
- Corresponding author at: Service d’Immunologie Clinique, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France. Tel.: +33 1 56 09 27 01; fax: +33 1 56 09 28 59.

Received 28 September 2009; received in revised form 5 November 2009; accepted 6 November 2009. published online 07 December 2009.

Abstract

Previous studies have suggested the efficacy of foscarnet combined with thymidine analogues as salvage therapy in late-stage HIV-1 infection. Here, we report on the first case of foscarnet therapy in a patient infected with HIV-2 exhibiting virologic failure. The patient was known to be HIV-2-infected since 1992 and had received 11 sequential lines of combined antiretroviral therapy (cART) with almost all the available antiretroviral agents including raltegravir. A marked decrease in HIV-2 plasma viral load of 1.48log₁₀copies/ml was observed at day 14 of foscarnet induction therapy associated with zidovudine and failing cART. An optimized cART was then introduced with lamivudine, zidovudine, lopinavir/r, etravirine and maraviroc. Four months after the end of foscarnet therapy, HIV-2 plasma viral load remained undetectable. This case report suggests that foscarnet may represent a therapeutic option for HIV-2-infected patients exhibiting multidrug resistance.